Search Within

Oscar Boutros Lahoud

Formats
  1. Meeting Abstract (88)
  2. Journal Article (37)
  3. Research Letter (6)
  4. Correspondence (2)
  5. Review (1)
Groups
  1. Department of Medicine (134)
  2. Hematologic Malignancies, Division of (134)
  3. Center for Hematologic Malignancies (130)
  4. Survivorship Research (126)
  5. Bone Marrow Transplant (124)
  6. CTCR Scholars (113)

More Groups

People
  1. Sergio Giralt (108)
  2. Gunjan Shah (106)
  3. Heather Landau (103)
  4. Michael Scordo (99)
  5. David Chung (93)
  6. Hani Hassoun (89)

More People

Years
  1. 2025 (2)
  2. 2024 (12)
  3. 2023 (42)
  4. 2022 (28)
  5. 2021 (10)
  6. 2020 (18)

More Years

Publications
  1. Blood (47)
  2. Clinical Lymphoma, Myeloma and Leukemia (26)
  3. Biology of Blood and Marrow Transplantation (10)
  4. Blood Advances (9)
  5. Journal of Clinical Oncology (8)
  6. Leukemia and Lymphoma (6)

More Publications

Publishers
  1. American Society of Hematology (56)
  2. Elsevier Inc. (41)
  3. American Society of Clinical Oncology (8)
  4. Nature Publishing Group (7)
  5. Taylor & Francis Group (6)
  6. John Wiley & Sons (3)

More Publishers

Results (134)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Utility of routine pulmonary function test after autologous hematopoietic cell transplantation in lymphoma
    Journal Article

    Dahi, P. B.; Kenny, S.; Flynn, J.; Devlin, S. M.; Ruiz, J. D.; Chinapen, S. A.; Lahoud, O. B.; Matasar, M. J.; Moskowitz, C. H.; Perales, M. A.; more...
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of commercially approved BCMAtargeting CAR-T therapy in triple-class refractory multiple myeloma
    Meeting Abstract

    Nishimura, N.; Brown, S.; Sean, M. D.; Parastoo, D.; Heather, J. L.; Oscar, B. L.; Michael, S.; Gunjan, L. S.; David, J. C.; Hani, H.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • The Simplified Comorbidity Index predicts non-relapse mortality in reduced-intensity conditioning allogeneic haematopoietic cell transplantation
    Journal Article

    Elias, S.; Brown, S.; Devlin, S. M.; Barker, J. N.; Cho, C.; Chung, D. J.; Dahi, P. B.; Giralt, S.; Gyurkocza, B.; Jakubowski, A. A.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial
    Journal Article

    Kubicki, T.; Dytfeld, D.; Wróbel, T.; Jamroziak, K.; Robak, P.; Czyż, J.; Tyczyńska, A.; Druzd-Sitek, A.; Giannopoulos, K.; Szczepaniak, T.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • A whole foods plant-based weight loss intervention improves metabolic and immune biomarkers in MGUS/SMM patients as well as progression trajectory in a subset: The NUTRIVENTION trial
    Meeting Abstract

    Shah, U.; Derkach, A.; Castro, F.; Anuraj, A.; Blaslov, J.; Hosszu, K.; Pollak, M.; Mailankody, S.; Korde, N.; Tan, C. R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Successful incorporation of ePRO using PROMIS-29 into standard of care after hematopoietic stem cell transplant and chimeric antigen receptor T cell therapy for plasma cell dyscrasias
    Meeting Abstract

    Shah, G.; Lobaugh, S.; Devlin, S.; Atkinson, T.; Korde, N.; Chung, D.; Dahi, P.; Landau, H.; Lahoud, O.; Hultcrantz, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Clinical significance of baseline body mass index and its trajectory during triplet induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Thirugnanasambandam, R. P.; Firestone, R.; Derkach, A.; Maclachlan, K.; Hultcrantz, M.; Mailankody, S.; Lahoud, O.; Landau, H.; Chung, D.; Shah, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) vs daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Tan, C. R.; Maclachlan, K.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Patel, D.; Shekarkhand, T.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Evolving M-spike and risk of progression in smoldering multiple myeloma
    Meeting Abstract

    Hultcrantz, M.; Nemirovsky, D.; Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Patel, D.; Shah, U.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Adding Plinabulin to pegfilgrastim to shorten neutropenia and improve quality of life peri-autologous hematopoietic cell transplant for multiple myeloma
    Meeting Abstract

    Shah, G.; Hanley, D.; Datta, A.; Kamrowski, A.; Chung, D.; Gupta, G.; Hassoun, H.; Hoover, E.; Hultcrantz, M.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save